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ABSTRACT 
Trichosanthin (TCS) is a type I ribosome-inactivating protein (RIP) with 
antiviral activity. It is a cytotoxic agent that inhibits Herpes Simplex Virus (HSV-1) 
and Human Immunodeficiency Virus (HIV-1) replication. The mechanism is not 
clear. There are evidences showing that TCS selectively induce apoptosis in HIV-1 
infected cells. This may inhibit viral replication due to premature host death. The 
present study demonstrates that TCS selectively induces cell death in HSV-1 
infected cells. Results showed that TCS is more cytotoxic in HSV-1 infected HEp-2 
cells than mock infected cells (TCgo 二 64.9 士 16.2 nM and 690 士 94.9 nM, 
respectively, p<0 .05) . The effect was more prominent in 0.1 MOI infection than 
0.01. Selective cytotoxicity was dose-dependent and observed only in low dosage 
group (0.05 -1 |iM), but not in high dosage group (1.85 - 7.4 |iM). Western blot 
analyses confirmed that the extent of caspase-3 activation in virus-infected cells, 
relative to their respective control, was greater in the low dosage group. In contrast, 
the effect of cycloheximide (CHX) was very different from TCS. CHX is a potent 
cytotoxic agent but never meant to be an antiviral agent. It was less cytotoxic in 
HSV-1 infected cells ( T C g o mock-.nfected = 102 士 10 n M ， T C g o Hsv-ntected = 549 土 141 nM, 
p<0 .05) . Our data suggests that antiviral action of TCS is not merely due to 
cytotoxicity but selective cytotoxicity toward HSV-1 infected cells. 
摘要 
天 花 粉 蛋 白 （ T C S ) 屬 於 具 有 抗 病 毒 活 性 的 I 型 核 糖 體 失 活 蛋 白 （ R I P ) ° 
它可以抑制單皰病毒 ( H S V - 1 )和人類免疫缺陷病毒 ( H I V - 1 )的複製。但是機理仍 
不清楚。有證據顯示 T C S 選擇性的引起 H I V - 1 感染的細胞調亡。當前的課題研 
究 T C S 在 急 性 H S V 感 染 中 的 選 擇 性 殺 傷 作 用 。 實 驗 結 果 顯 示 相 對 於 類 比 感 染 
的細胞，TCS有效地引起HSV-1感染的HEp-2細胞死亡（TCgo二 64.9 士 16.2 nM 
a n d 6 9 0 士 9 4 . 9 n M , r e s p e c t i v e l y , p < 0 . 0 5 ) 。 0 . 1 M O I 的感染相對於 0 . 0 1 M O I 較 
為顯著。選擇性殺傷僅在低劑量（0 . 0 5 - 1 ^ i M ) 時被發現，而在高劑量時則沒有 
( 1 . 8 5 - 7 . 4 ^ M ) 。 W e s t e r n b l o t 分析確證在病毒感染細胞中，相對於對照，低劑量 
時 c a s p a s e - 3啟動很為顯著。作為比較，當前課題用另外一個殺傷性試劑環己醜 
亞胺 ( C H X ) 去做相同實驗。 C H X 不曽被發現在感染細胞中有抗病毒效應。實驗 
結果顯示相對於類比感染的細胞，C H X對H S V - 1感染細胞有較小的殺傷 ( T C 8 0 
mock- in fec ted102 士 1 0 n M , TCgO H S V - m f e c t e d = 5 4 9 士 1 41 n M , / 7 < 0 . 0 5 ) ° 我們的數據顯 
示著 T C S 的抗病毒功能不僅僅歸於殺傷作用，而是選擇性地殺傷受 H S V - 1 感 
染的細胞。 
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This thesis will explore the relationship between cytotoxicity of Trichosanthin 
(TCS) and its antiviral activity. The emphasis will be on selective cytotoxicity of this 
protein in virus-infected cells and the implication in its antiviral action. In this study, 
we use a cellular model acutely infected with Herpes Simplex Virus Type 1 (HSV-1). 
The nature of the selective killing may be apoptosis. Before looking into the 
experimental detail and data, a brief understanding of the biology of TCS, apoptosis 
and HSV is required. 
TRICHOSANTHIN 
Trichosanthin is a 27kDa type I ribosome-inactivating protein (RIP) 
characterized in the root tuber of the Chinese medicinal herb Trichosanthes kirilowii 
Maximowicz (Tian Hua Fen). The ribosome-inactivating (RI) activity of RIPs, 
including TCS, is attributed to the rRNA-N-glycosidase activity (EC 3.2.2.22) of the 
protein. RI activity is accounted by the removal of a single adenine residue (八4324 in 
rat liver rRNA) from a GAGA sequence in a universally conserved loop in 28S 
rRNA of 60S large subunit, the so-called sarcin/ricin domain (SRD) (Zhang and Liu, 
1992). This inhibits the binding of elongation factors that partipicate in mRNA 
translation to the SRD and arrests translation in the elongation phase. 
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Figure 1.1. Schematics of Type I and II RIPs (Stirpe and Battelli, 2006) 
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RIP can be catergorized into type I and II (Figure. 1.1). Type I RIPs consist of 
A-chain only, which is the entity responsible for the toxicity of all RIPs. B-chain, 
with properties of lectins specific for galactose, N-acetylgalactosamine or N-acetyl 
neuraminic acid, is found to be disulphide-linked with A-chain in type II proteins. 
The lectin activity of B-chain allows type II RIPs to interact with membrane 
glycolipids and glycoprotein, facilitating their endocytosis process (Stirpe and 
Battelli, 2006). In general, type II proteins can enter into the cells much easier than 
type I proteins and are therefore more cytotoxic. Although the entry and intracellular 
transport mechanisms of type II proteins have been studied extensively (mostly 
modeled by ricin), the endocytosis mechanism of type I RIPs is still not well known. 
Being a type I RIP, TCS lacks the B-chain for facilitating internalization by the cells. 
However, to carry out its function, TCS should enter into the cells to reach the 
cytoplasm. In this regard, many studies have been carried out to elucidate the 
mechanism of how TCS enters the cell. 
Receptor-mediated endocytosis 
TCS is highly toxic to choriocarcinoma JAR cells but is relatively less toxic to 
hepatoma H35 cells (Tsao et al., 1986; He et al., 1999a; He et al.，1999b). It is 
thought that the difference in cytotoxicity is related the rate of entry of TCS into the 
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cells (Chan et al., 2003). In one study, it was found that the amount of TCS entered 
into JAR cells was greater than that of H35 cells in fixed period of time (Chan et al., 
2003). This suggested that there is a special mechanism for the entry of TCS into 
choriocarcinoma JAR cells (Chan et al” 2000). TCS was found to interact with 
LDL-receptor related protein (LRP) and megalin and the binding is inhibited by 
receptor associated protein (RAP) (Chan et al., 2000). It was shown that the uptake 
of TCS by JAR cells, which expresses LRP, was indeed inhibited by LRP ligand 
receptor-associated protein (RAP), suggesting that the internalization of TCS into the 
JAR cells is mediated by the LDL receptor family (Chan et al., 2000). Because 
megalin mediated the endocytosis of TCS (Chan et al., 2000), the abundance of 
megalin in proximal tubule epithelial cells in kidney can account for the fact that 
high concentration of TCS damaged the proximal tubules in kidney (Tang et al.， 
1997). 
Following endocytosis, TCS was directed into endosomal compartments where 
pH is acidic. It is currently unknown how TCS reaches cytoplasm. Nevertheless, 
recently studies revealed that TCS may interact with membrane phospholipids. It was 
found that the tertiary structure of TCS would be changed when TCS was placed in a 
low pH microenvironment, which exposed more hydrophobic sites (Xia and Sui, 
2000). Therefore, TCS may interact with the phospholipid-containing monolayer 
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under acidic conditions through hydrophobic interaction (Lu et al., 2001). This may 
allow membrane translocation of TCS into cytoplasm. The deletion of seven amino 
acids at the C-terminal of TCS reduced its membrane insertion ability, reflecting the 
importance of the C-terminal in the translocation process (Zhang et al., 2003). 
Biological Activities 
Trichosanthin is found to possess various biological activities, including abortifacient, 
antitumor, and also antiviral activity. 
Abortifacient activity 
The extract of the roots of the Cucurbitacea T. kirilowii have been used in 
traditional Chinese medicine to induce abortion and is an effect attributed to 
trichosanthin. This activity was later found to be common to all RIPs tested. RIPs 
cause the death of the fetus by killing syncytiotrophoblasts, cells that are highly 
sensitive to RIPs (Battelli et al., 1992). The abortifacient activity of trichosanthin was 
attributed to its effect on ribosomes, albeit other mechanisms may also exist as 
discussed below. 
6 
Antitumor and pro-apopotic activity 
Apoptosis is a mode of programmed cell death which would be described in 
greater detail in later part of this chapter. TCS was found to stimulate the production 
of reactive oxygen species (ROS) and apoptosis in JAR cells (Zhang et al.，2000; 
Zhang et al., 2001). Presumably, TCS induces the apoptosis of JAR cells via ROS 
production, intracelluar Ca^^ elevation and caspase-3 activation (Zhang et al., 2001). 
The production of ROS was shown to be dependent on extracellular as well as 
intracellular calcium levels and was found to parallel calcium elevation, suggesting 
that ROS production might be a consequence of calcium signaling. Anti-oxidant 
Trolox and ROS scavengers catalase and mannitol were able to rescue the cells from 
TCS-induced cell death. This further substantiates the idea that TCS induce apoptosis 
in JAR cells may involve ROS production. 
One may immediately relate the RI activity of RIPs with apoptosis. In fact, it 
was shown that ricin, a-sarcin were able to activate the Jun N-terminal Kinase, JNKl 
in Rat-1 cells (lordanov et al., 1997). The group characterized a novel pathway of 
kinase activation caused by damage of 28S rRNA, namely ribotoxic stress response 
which resulted in activation of JNK and its activator SEK1/MKK4. The study also 
revealed that activation of JNKl is not just due to protein synthesis inhibition, but 
also due to signaling from 28S rRNA affected by RIPs. Further, not all inhibitors of 
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protein synthesis were able to elicit the ribotoxic stress response. Hence, it was 
proposed that ribotoxic stress response is specific for RIPs that damage the SRD of 
28S rRNA. However, it is currently uncertain whether TCS could induce JNK 
activation, and hence apoptosis via the ribotoxic stress response. 
Antiviral Activity 
TCS inhibited the replication of human immunodeficiency virus type 1 (HIV-1) 
in both acutely infected T-lymphoblastoid cells and chronically infected macrophages 
in vitro (McGrath et al., 1989). For the antiviral mechanisms, apparently, it was 
believed that anti-HIV activity is related to its RI activity. It was shown that two TCS 
variants, [KIRE120-123SAGG]TCS and [E160A-E189A]TCS, having 4000- and 
1800-fold reduction in RI activity, respectively, were devoid of anti-HIV activity 
(Wang et al., 2002). However, it was later found that two TCS variants, namely 
TCSC19aa and TCSKDEL, having a 19 amino acid extension and a KDEL (a ER 
retention signal) signal sequence added to the C-terminal sequence, respectively, lost 
most of the anti-HIV activity but ribosome-inactivating activity was retained (Wang 
et al., 2003). As a matter of fact, not all RIPs are antiviral (Stirpe and Battelli, 2006). 
Therefore, other mechanisms may contribute to the anti-HIV activity of TCS. 
Apoptosis was found to be increased in TCS-treated HIV-1 infected cells (Wang et al., 
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2005). At this stage, it is still puzzling whether this enhanced apoptotic action of TCS 
in HIV-1 infected cells contribute to its antiviral activity. 
In addition to anti-HIV activity, TCS was also known to inhibit the replication 
of Herpes Simplex Virus Type 1 (HSV-1) in vitro (Zheng et al., 2001). At molecular 
level, TCS was found to interfere with the intracellular mitogen-activated protein 
kinase (MAPK) pathway, which is thought to mediate a multitude of cellular events 
including cell proliferation, cellular response to stress and also apoptosis. 
Specifically, the elevation of the protein level of phosphorylated p38, a family 
member of the MAPK superfamily, and also the anti-apopotic protein BCL-2, 
induced by HSV-1 infection was suppressed upon treatment with TCS (Huang et al., 
2006). This was accompanied by the reduction of HSV-1 antigen level (Huang et al., 
2006). These data suggested that the anti-HSV action of TCS may involve the 
MAPK pathway. 
In this study, we explore the cytotoxicity of TCS in cells acutely infected with 
HSV-1. An understanding of the cell-killing mechanism, specifically apoptosis, and 
also HSV biology is therefore essential. 
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APOPTOSIS 
Apoptosis is a form of programmed cell death (PCD) which can occur in many 
physiological and pathological conditions. Unlike necrosis which is a form of cell 
death triggering immune response due to release of cellular content into the 
extracellular space, cells that undergo apoptosis are typically engulfed by 
professional phagocytes and the cellular content is subsequently degraded. This 
minimized damage and disruption to the neighboring cells. 
Apoptosis is a mode of cell death that is characterized base on morphological 
and biochemical criteria at the cellular level (Kerr et al.，1972). Typical morphology 
of apoptotic cells includes: rounding and retraction from the neighboring cells, 
plasma membrane blebbing with budding of vesicular structure known as apoptotic 
bodies, organelle fragmentation, with nuclear fragmentation being the most obvious 
and distinctive that cannot be observed in any other circumstances (Taylor et al., 
2008). Endoplasmic reticulum (ER), mitochondrial and Golgi networks breakdown 
are more subtle (Taylor et al., 2008). These phenotypical events can be accounted 
mostly by the central player in the apoptotic pathway, namely, caspase. 
Caspase is a family of proteases synthesized by the cells as zymogens (enzyme 
precursors) and required proteolytic cleavage for activation (Stennicke and Salvesen, 
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2000; Stennicke, 2000; Stennicke and Salvesen, 1998). An essential cysteine 
residue is found in the active site and an aspartate residue is required for enzymatic 
function at the substrate cleavage site. Functionally, initiator caspases are activated in 
response to stimuli and effector caspases are the actual 'executioner' that acts on 
different cellular substrates. Caspase are known to act on more than 400 substrates, 
comprising the so-called caspase substrate database (Taylor et al., 2008). With 
respect to the demolition at the cellular level, for example, caspases act on 
cytoskeletal elements like act in microfilaments, thereby weakening cytoskeletal 
support and as the cell cytoplasm flows against unspported areas of the plasma 
membrane, membrane blebbing occurs (Taylor et al., 2008). This is an example 
linking the morphology of apoptotic cells with activities of caspase. 
Essentially, caspase activation can occur via three pathways: the extrinsic, 
instrinsic and granzyme B pathway. 
Extrinsic Pathway 
Extrinsic pathway is also known as the death receptor-dependent pathway. The 
later name implies a role of membrane receptors in mediating cell death. The 
membrane receptors tumor necrosis factor-a (TNF-a) receptor and Fas are the two 
most extensively studied. Binding of the cognate ligands, TNF-a and FasL 
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respectively, to the receptors induces the interaction of a portion ofthe cytoplasmic 
domain (death domain, DD) of the death receptors with an adaptor molecule called 
Fas-associated death domain protein (FADD). The complex then recruits and 
aggregates many molecules of the initiator caspase, caspase-8, thereby stimulating its 
autoprocessing and activation. The interaction is mediated by the death effector 
domain (DED) on both FADD and caspase-8. The whole molecular assembly is 
coined the death-inducing signaling complex (DISC) and is the central molecular 
platform in the extrinsic pathway. The active caspase-8 can act on effector caspases, 
caspase-3 and -7 directly, provoking further activation of caspases and substrate 
proteolysis. 
Intrinsic Pathway 
Central regulators of this pathway include the B-cell lymphoma-2 (BCL-2) 
family of proteins (Tsujimoto et al., 1985). This family consists of both 
anti-apoptotic and pro-apoptotic proteins, which share sequence homology within 
conserved regions known as the BCL-2 homology (BH) domains. BH domains 
correspond to helical segments that dictate structure and function. All anti-apoptotic 
members, such as BCL-2 and BCL-XL, and a subset of pro-apoptotic family 
members, such as BAX and BAK, are multidomain proteins sharing sequence 
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homology within three to four BH domains. The BH3-only subset of pro-apoptotic 
molecules, including BAD, BID, BIM, NOXA, BIK, HRK, and PUMA, show 
sequence homology only within a single a helical segment, the BH3 domain, which 
is also known as the minimal death domain required for binding to multidomain 
BCL-2 family members. The ability of BCL-2 proteins to selectively bind each other 
is intergral to their function. Different stimuli that provoke cell stress or damage 
generally activate one or more members of the BH3 only protein family. They are 
pathway-specific sensors for various stimuli and are regulated in distinct ways and 
this allows convergence of different cellular stress signals into the death pathway. 
BH3-only protein activation above a crucial threshold overcomes the inhibitory 
effect of the anti-apoptotic family members and promotes the assembly of 
BAK-BAX oilgomers within mitochondrial outer membranes. These oligomers form 
pores that permit the efflux of mitochondrial intermembrane space proteins, such as 
SMAC/DIABLO and cytochrome c, the latter being a component of the 
mitochondrial electron transport chain, into the cytoplasm. On release from 
mitochondria, cytochrome c can seed apoptosome assembly. Apoptosome is 
composed of seven molecules of apoptotic protease-activating factor-1 (APAF-1) and 
the same number of caspase-9 homodimers and cytochrome c. This complex is the 
central molecular platform in the intrinsic pathway. Formation of apoptosome 
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activates caspase-9, and the active caspase-9 then propagates a proteolytic cascade of 
further caspase activation events. 
Pathway crosstalk 
In some situations, extrinsic death signals can crosstalk with the intrinsic 
pathway through caspase-8-mediated proteolysis of the BH3-only protein BID. 
Truncated BID (tBID) can promote mitochondrial cytochrome c release and 
assembly of the apoptosome. 
Granzyme B pathway 
This pathway of caspase activation involves the delivery of this protease called 
granzymes into the target cell through specialized granules that are released from 
cytotoxic T lymphocytes (CTL) or natural killer (NK) cells. CTL and NK granules 
contain numerous granzymes as well as a pore-forming protein, perforin, which 
oligomerizes in the membranes of target cells to permit entry of the granzymes. 
Granzyme B, similar to the caspases, also cleaves its substrates after Asp residues 
and can process BID, caspase-3 and -7 to initiate apoptosis. 
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Viral manipulation of apoptotic pathway 
It is thought that virus possesses ability to resist apoptosis of host cells. The 
argument is based on the fact that viral survival is dependent upon the effective 
exploitation of cellular machinery. Cell death therefore inhibits viral replication and 
is not desirable from viruses' perspective. A virus may need to interfere at only a 
single point within the cell death program to maintain a viable host cell. A variety of 
gene products are encoded by viruses to achieve this. This may include, for example, 
BCL-2 homologs or proteins that interact with BCL-2 family and caspase 
suppressors. For instance, the gammaherpesvirus Epstein-Barr virus (EBV) prevent 
apoptosis by encoding the viral protein LMP-1 (Grimm et al., 2005; Klein, 1996). 
This upregulates host cell BCL-2 level and also other cellular antiapoptotic proteins. 
In addition, EBV encodes an homolog of BCL-2, designated BHRF-1 (Khanim et al., 
1997). 
Viruses also encode caspase inhibitors. In particular, some viruses give rise to 
protein called inhibitor of apoptosis (lAP). lAPs were initially identified as cellular 
proteins which exert its effect on both initiator and effector caspases. The viral 
orthologs are clearly inhibitor of apoptosis. 
The virus used in our study is HSV-1 which was known to possess multiple 
strategies to fight against apoptosis. A general description of HSV biology would be 
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the final task of this chapter. 
HERPESVIRUSES 
Herpes simplex virus is a member of the Herpesviridae family. Membership in 
this family is based solely on virion structure and is independent of sequence 
similarity. Nevertheless, most herpesviruses share varying degrees of sequence 
similarity and many biological functions. All Herpes virions consist of a core 
composed of proteins and linear, double-stranded DNA, enclosed in an icosahedral 
capsid. The capsid is surrounded by the tegument, an amorphous mass of proteins. 
The entire virion is coated with a lipid envelope containing glycoprotein spikes. 
Although all herpesviruses' structure shares this basic plan, the components that 
make up the core, capsid, tegument and envelope can vary (Taylor et al., 2002). 
There are eight known human herpesviruses and more than 130 total known 
herpesviruses. They are divided into three subfamilies, alpha, beta and gamma, 
which differ in their host ranges, kinetics of replication and tissue specificities. The 
ability to establish latent infection is the major characteristic of herpesviruses. The 
mechanisms of establishment of, maintenance of, and reactivation from latency are 
different for each herpesviruse. Nevertheless, all herpesviruses demonstrate the 
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hallmark of latency: circularization of the viral genome within the nucleus and 
limited gene expression. Upon reactivation, these circular genomes, which can exist 
as several copies in a host cell, replicate and the viral progeny can cause diseases. 
Viruses in the Herpesviridae family have genome size range from 120 to 250 
kilo base pairs (kbp). Genomes of herpesviruses have about 70 to 200 genes, most of 
which, with a few notable exceptions, share the same general characteristics, 
including a TATA box, upstream promoter and/or regulatory sequences, and a 
transcription initiation site 20-25 bp downstream of the TATA box. Herpesviral genes 
are generally unspliced and the gene ends with a typical polyadenylation signal, with 
the later being the signature of eukaryotic mRNA transcript. All herpesviruses 
express their genes in a regulatory cascade and they utilize both viral and cellular 
transcriptional regulators. The host RNA polymerase II is employed by the virus to 
transcribe almost all herpesviral genes. Some herpesviruses' regulatory proteins 
interact with cellular transcription factors or with RNA polymerase II itself to 
regulate viral gene transcription. Herpesviruses tend to express proteins that alter the 
host cell in various ways to create a cellular environment favourable for viral 
replication. Most herpesviruses do not immortalize their natural host cells, except 
EBV. They attempt to evade the host immune system by encoding a variety of 
immune evasion proteins. Herpesviruses have evolved into successful intracellular 
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parasites: they cause diseases, but rarely death, in their natural hosts ; Reactivation 
from latent infection allows perpetuation inside the host. 
Herpes Simplex Virus Type 1 
Herpes simplex virus is a member of the alphaherpesvirus subfamily and is 
characterized by a broad host range, a rapid reproductive cycle and latent infection in 
sensory neurons. HSV-1 initially infects the mucosal epithelia, and this productive 
infection leads to vesicular lesions, commonly known as cold sores. The virus then 
spreads to sensory neurons and establishes latent infection there. The normal course 
of infection is not lethal, but the virus can remain in the host throughout the life, with 
sporadic recurrences. 
Virion structure 
The HSV particle, like all herpesviruses, consists of a nucleocapsid containing 
the viral DNA and an icosahedral capsid, a layer of proteins embracing the capsid 
called the tegument, and this is all surrounded by the nuclear envelope containing 
glycoprotein spikes (Figure 1.2). 
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Figure 1.2. HSV Virion Structure 
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Viral Genome 
HSV DNA is packaged into the core of the virion as a linear, double-stranded 
structure. The genome size of HSV- 1 is about 152 kbp. Each genome consists of 
long (L) and short (S) segments, which are covalently linked. These segments 
contain unique sequences flanked by inverted repeats (Figure 1.3) (Roizman et al., 
1975). The L and S components can invert relative to each other via recombination 
during DNA replication, and, in a wildtype infection, the four possible isomers are 
present in equimolar concentrations (Roizman, 1976; Hay ward et al., 1975). Each 
genome contains three origins of replication, one copy of OriL in the unique long 
segment, and two copies of OriS in the repeat sequences (Taylor et al., 2002). 
Capsid, Tegument and Envelope 
The DNA is surrounded by a protein capsid. It is made up of 162 caspsomers. 
Surrounding the capsid is the tegument. This is an amorphous mass of proteins, 
including VP 16, which is important for the stimulation of viral gene expression, and 
the vhs protein, which plays a role in shutting off translation of host proteins. A lipid 
membrane which contains numerous viral glycoprotein spikes, many of which are 
necessary for entry, surrounds the tegument. 
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Figure 1.3. Schematic of the genome organization of HSV-1 (Taylor et al., 2002) 
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HSV Life Cycle 
The HSV productive infection cycle is depicted in Figure 1.4. Virions enter 
into the cell via fusion of the envelope with the plasma membrane. This is followed 
by the transport of the nucleocapsid to the nucleus of the cell, circularization of the 
genome, initiation of viral gene expression, DNA replication, viral gene expression, 
packaging of the virion, envelopment and egress. 
Entry and Transport of Capsid to Nucleus 
The viral glycoproteins used for entry of the virion into the host cell include 
gB, gC, gD, and the gWgL complex (Spear, 2004) . Initially, gC binds to heparin 
sulfate on the surface of the cell. However, this step is not essential, as HSV can still 
infect cells that lack heparan sulfate, albeit with lower efficiency (Spear, 2004). In 
addition to the gC-heparan sulfate interaction, gD binds to one of the newly 
identified herpes virus entry mediator, the HVEM which belongs to TNF receptor 
superfamily (Spear, 2004). It is this interaction, as well as, gB and gWgL, essential 
for fusion of the viral envelope with the plasma membrane of the cell. During fusion, 
the tegument proteins and the nucleocapsid are released into the cytoplasm. The 
nucleocapsid is then transported by microtubules to the nuclear pore, where the viral 
DNA is translocated into the nucleus. The emptied capsids accumulate at nuclear 
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Figure 1.4. HSV life cycle (Taylor et al., 2002) 
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pore complexes (Taylor et al., 2002). Some of the tegument proteins are translocated 
into the nucleus (e.g. VP 16，VP 1-2), while others remain in the cytoplasm (e.g. vhs). 
Once inside the nucleus, the viral genome rapidly circularizes and viral gene 
expression initiates. 
Viral gene expression 
Viral gene expression is temporally regulated. The genes are categorized into 
three classes based on the timing of their transcription: immediate early or a genes, 
early or p genes, and late or y genes. The late genes are further divided into two 
subclasses, leaky-late (yl) and true late (y2). y2 gene expression is strictly dependent 
on viral DNA synthesis. All viral mRNAs are transcribed by the host's RNA 
polymerase II, but the regulation of transcription involves both viral and cellular 
transcriptional activators and repressors. 
Encapsidation and Egress 
After the late genes are expressed and the viral DNA is replicated, virion 
assembly begins. The DNA is cleaved into monomers and packaged into assembled 
capsids in the nucleus. The self-assembled property of capsid proteins accounts for 
the temporal regulation of late gene expression: if the capsid proteins were expressed 
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prior to DNA replication, they would be assembled and the nucleus would be full of 
empty capsids. This would hinder the formation of mature, full virions and would 
inhibit proper viral replication. Once the capsids are assembled, they are loaded with 
DNA. After the DNA is packaged, the capsid is enveloped and leaves the cell. The 
nucleocapsid can bud through the inner nuclear membrane and become enveloped. 
Two models have been proposed to explain the remaining events (Taylor et al., 2002). 
A reenvelopment model suggests that enveloped virions fuse with the outer nuclear 
membrane, thereby releasing nucleocapsids into the cytoplasm that re-envelope by 
budding into the Golgi apparatus. These re-enveloped particles are secreted out the 
cell by via vesicular transport. A lumenal pathway model proposes that enveloped 
virions move from the inner nuclear space to the Golgi in vesicles, or within the 
lumen of the endoplasmic reticulum, and are released from the cell by a normal 
secretory route. 
Latent Infection 
One of the unique features of all herpesviruses is the ability to establish latent 
infection in the host. Herpes simplex virus infects and becomes latent in sensory 
neurons, specifically the trigeminal ganglia for HSV-1. During latency, production of 
viral progeny is suppressed, and there is limited viral gene expression. A latent 
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infection is established after primary infection of epithelial cells leads to spread of 
the virus into neighboring neurofial termini. The nucleocapsid is transported along 
the axon to the neuronal cell body. During latency, lytic gene products are not 
produced and the DNA remains in a circular, extrachromasomal form inside the 
nucleus of the ganglion. The shutdown of viral gene expression may allow the virus 
to evade host's immune system. The virus will remain latent, occasionally reactivated, 
for the lifetime of the host. Reactivation is often due to physical or emotional stresses, 
involving the viral replication in the neurons, follow by traveling back to the site of 
the primary infection along the axon. In latently infected cells, only one viral gene is 
expressed at the transcriptional level, namely latency-associated transcripts (LATs). 
This entity was not found to encode for any protein. The story become clear when a 
group discovered that the LAT gene actually encode for a microRNA (miRNA), a 
class of small RNAs regulating gene expression at post-transcriptional level. The 
novel miRNA was coined miR-LAT and was found to be anti-apoptotic by 
modulating the transforming-growth factor-p (TGF-p) pathway (Gupta et al., 2006). 
This allows the virus to maintain latent infection in sensory neurons, without killing 
host cells and triggering immune response. 
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HSV-1 regulation of apoptosis 
Physiologically, apoptosis is an important part of the innate immune response. 
Elimination of the virus-infected cells by apoptosis can decrease the production and 
spreading of infectious viral progeny. Many viruses have evolved ways to battle 
against apoptosis induction. A number of HSV-1 genes have been demonstrated to 
block apoptosis. Some reports demonstrated that two virion components, gD and gJ, 
possess anti-apoptotic activity. 
The function for gD in terms of apoptosis was demonstrated by a report 
showing that gD was sufficient to block apoptosis induced by Fas Ligand (FasL) 
(Medici et al., 2003). In the same study, it was found that purified gD could stimulate 
N F K B (a transcription factor regulating cell survival) activity, thereby upregulated 
the expression of anti-apoptotic cellular genes. 
Another viral protein gJ is a 92 amino acid membrane associated glycoprotein. 
It was first implicated as an anti-apoptotic factor when cells infected with a gJ 
deletion virus were found to be susceptible to cell death induced by FasL (Zhou et al., 
2000). The mechanism of the anti-apoptotic action of gJ remains unclear. 
Other viral factors, like Us3 which is a viral protein kinase, were found to 
block apoptosis via different mechanisms like preventing processing of procaspase-3 
(Mori et al., 2003; Cartier et al., 2003; Munger and Roizman, 2001; Jerome et al., 
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1999; Leopardi et al., 1997). 
Conclusion 
To conclude, it is clear that virus like HSV-1 has evolved strategies in 
preventing cell death. It is therefore logical to speculate that if TCS can selectively 
induces cell death in virus-infected cells, as already shown in HIV-1 infected cells 
(Wang et al., 2005), it can potentially serve as an antiviral therapeutics because 
premature cell death in the context of viral infection may prevent viruses from 
utilizing cell machinery for production of more viral progeny. This thesis would 
address the role of cytotoxicity of TCS in HSV-infected cells. It is an acute infection 
as compared with HIV infection which is chronic. 
In this thesis, chapter 2 illustrates the methodology employed in this study and 
the result presented (chapter 3) will be discussed in chapter 4. 
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Chapter 2 
Materials and Methods 
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Cell lines and virus 
All cells were maintained in Dulbecco's modified Eagle's medium containing 
10% fetal bovine serum. HEp-2 and HSV-1 (F) were obtained from the American 
Type Culture Collection (Rockville, MD, USA). HSV-1 was propagated in HEp-2 
ceil monolayer and virus was purified with differential centrifugation. In brief, 
medium of cell culture infected for 48 h at 37 °C was collected and spin at 10000 g at 
4 °C for 20 mins to remove cell debris. Supernatant was collected and subjected to 
further centrifugation at 50000 g at 4 °C for 2 h. Supernatant was discarded and 
pellet was resuspended in serum-free DMEM and stored at -80 °C. 
Infectivity assay 
A quantal assay was used to measure the titer of infective virus. In this assay, 
each inoculated subject either responds or it does not (all-or-none response); in our 
case, for example, an inoculated cell culture either develops a cytopathic effect (CPE) 
or it does not. CPE is recorded 48 h postinfection. The aim of the assay is to find the 
virus dose that produces a response in 50 per cent of inoculated subjects (figure 2.1). 
In cell culture assays this dose is known as the TCID50 (the dose that infects 50 per 
cent of inoculated tissue cultures). The outcome of a TCID50 determination can be 
used to estimate a virus titer in plaque-forming unit, or vice versa, using the formula 
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Figure 2.1. Example of a TCID50 assay, (a) Tenfold dilutions of the virus were 
inoculated into cell cultures grown in the wells of a plate. Each well received 1 ml 
virus suspension, except for the control wells, which each received 1 ml diluent, (b) 
After incubation the cell culture in each well was scored ‘+’ or ‘—’ for CPE. 
(c) The results of the assay. (From J. Carter and V. Saunders, (2007) Virology: 
Principles and Applications, Wiley) 
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1 TCIDso = 0.7 pfu, provided if the method used to visualize plaques does not alter 
the yield of virus. In this study, virus titer was measured in terms of TCID50. An 
example of a TCID50 determination is depicted in Figure 2.1. In this example, it is 
clear that the dilution of virus that contains one TCID50 lies between and lO— .^ 
Reed-Muench method was used for estimating this end point and the method was 
demonstrated in figure 2.2. 
Treatment of cells and virus infection 
For both MTT assay and ELISA, 100 i^l of HEp-2 cells (1x10^ cells/ml) were 
seeded onto a microtiter plate and allowed to attach to the bottom of wells. Various 
concentrations of TCS (Shanghai Jinshan Pharmaceutical Limited Company, 
Shanghai, PRC) or cycloheximide (Sigma), were added and incubated for 48 h. 
Cycloheximide (CHX) is a well known cytotoxic agent but never claim to possess 
specific antiviral activity. Selective and non-selective cytotoxicity can be compared. 
This may bring out the role of selective cytotoxicity of TCS. 
All incubation steps were done at 37 °C in a humidified atmosphere of 5% CO2. 
In case of viral infection, TCS was added 2 h postinfection (hpi) and the virus doses 
were either 0.01 or 0.1 multiplicity of infection (MOI). The multiplicity of infection 
is the average number of virus per cell. The MOI is determined by simply dividing 
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The Reed-Muench method for estimating TCIDsa 
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"The infection ratio is the number of positives for the cumulative value out of the total for the cumulative value. 
^Thc % infection is the infection ratio converted to a pcrccntagc. 
It had already been determined thai the dilution of virus that contains one TCID50 lies between tO~- and 
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The concentration of virus in the undiluted suspension is 3.2 x 10-^  TCIDsj/ml. 
Figure 2.2. Reed-Muench method for determination of infective viral titer. (From J. 
Carter and V. Saunders, (2007) Virology: Principles and Applications, 
Wiley) 
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the number of virus added (ml added x T C I D s o / m l ) by the number of cells seeded. 
Although the MOI tells the average number of virus per cell, the actual number 
of virus that infect any given cell is a statistical function. 
MTT assay for cytotoxicity 
MTT assay is colorimetric assay for measuring cellular growth. It can also be 
used to determine cytotoxicity of compounds. 
Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
tetrazole) is reduced to purple formazan in the mitochondria of living cells by 
dehydrogenase. A solubilization solution (usually either dimethyl sulfoxide, an 
acidified ethanol solution, or a solution of the detergent sodium dodecyl sulfate in 
dilute hydrochloric acid) is added to dissolve the insoluble purple formazan product 
into a colored solution. The absorbance of this colored solution can be quantified by 
measuring at a certain wavelength by a spectrophotometer. The absorption maximum 
is dependent on the solvent employed. This reduction takes place only when 
mitochondrial dehydrogenase are active, as in the case of viable (living) cells, and 
therefore conversion can be directly related to the number of viable (living) cells. 
When the amount of purple formazan produced by cells treated with an agent is 
compared with the amount of formazan produced by control cells, the cytotoxicity of 
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the compound can be deduced through the production of a dose-response curve. 
In this study, cytotoxicity was measured by the MTT method using the Cell 
Proliferation Kit I (Roche Applied Science) according to manufacturer's instruction. 
Briefly, 10 of MTT reagent was added to the treated cells and after 4 h incubation, 
100 [l\ of solubilization buffer was added. After the formazan product was 
completely dissolved, absorbance of color complex was read at 550 nm with 
reference wavelength at 690 nm. 
Preparation of cell lysate 
Typically, 1 w e r e seeded in 6-well plates. After treatment, aspirate medium 
from cells. Rinse cells once with PBS (137 mM NaCl, 10 mM NasHPOj, 2.7 mM 
KCl, 1.8 mM KH2PO4, pH 7.4). Add 200 of CytoBusterTM protein extraction 
reagent (Novagen) together with protease inhibitor cocktail (Roche Applied Science), 
and incubate on ice for 5 min. To maximize recovery, scrape cell debris using a cell 
scraper (rubber policeman). Orient the plate so that all debris is pooled in the 
CytoBuster Protein Extraction Reagent Transfer extract to a suitably size tube and 
spin for 5 min at 16,000 x g a t 4 °C. Transfer supernatant (cell extract) to a new tube 
and proceed with analysis. 
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Bradford assay for protein concentration 
The protein assay is a dye-binding assay in which a differential color change of 
a dye occurs in response to various concentrations of protein. The absorbance 
maximum for an acidic solution of Coomassie® Brilliant Blue G-250 dye shifts from 
465 nm to 595 nm when binding to protein occurs and was measured 
spectrophotometrically. Thus, Beer-Lambert law may be applied for accurate 
quantitation of protein. The Coomassie blue dye binds to primarily basic and 
aromatic amino acid residues, especially arginine. 
Protein assay was performed according to manufacturer's instruction 
(Bio-Rad). Prepare dye reagent by diluting 1 part Dye Reagent Concentrate with 4 
parts ddHsO. Filter through a Whatman filter (or equivalent) to remove 
particulates. Prepare three to five dilutions of bovine serum albumin protein standard. 
Protein solutions are normally assayed in duplicate or triplicate. Pipet 10 |il of each 
standard and sample solution into separate microtiter plate wells. Add 200 [i\ of 
diluted dye reagent to each well. Mix the sample and reagent thoroughly using a 
microplate mixer. Alternatively, use a multi-channel pipet to dispense the reagent. 
Depress the plunger repeatedly to mix the sample and reagent in the well. Replace 
with clean tips and add reagent to the next set of wells. Incubate at room temperature 
for at least 5 minutes. Absorbance will increase over time; samples should incubate 
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at room temperature for no more than 1 hour. Measure absorbance at 595 nm. 
Western blot analysis 
Cell lysate samples (25 jug total protein per lane) were separated by 
SDS-PAGE (5% stacking, 12 % resolving gel, 100 V for 4 h)，then semi-dry 
transferred (70 V for 1 h) to polyvinylidene difluoride membranes (Immobilon P, 
Millipore, Bedford, MA, USA). Membranes were blocked for 1 h at room 
temperature in 5 % skimmed milk in TBST (20 mM Tris-HCl (pH 7.6), 137 mM 
NaCl containing 1 % Tween 20), and then probed with primary antibody against 
procaspase-3, BCL-2 (Cell Signaling Technology Inc.) (1:1000). During apoptosis, 
procaspase-3 is cleaved. Therefore, loss of procaspase-3 immunoreactivity 
corresponds to apoptosis induction in our system. This was followed by reaction with 
horseradish peroxidase-conjugated secondary antibody (DAKO, Denmark) (1:2000). 
Blots were detected with the ECL Western Blotting Detection Reagent (Amershan 
Biosciences, Little Chalfont, UK) and exposed to X-ray films (Fuji Photo Film Co., 
Japan). Densitometry was performed with FluorChem 8000 (Alpha Innotech Co., 
San Leandro, CA, USA) according to manufacturer's instruction. P-actin was 
employed as the internal control (Cell Signaling Technology Inc.) (1:2000). 
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Enzyme-linked immunosorbent assay (ELISA) for quantification of 
HSV-1 antigen 
Quantity of HSV-1 antigen was determined by in situ ELISA (Zheng et al., 
2001; Rabalais et al., 1987; Berkowitz and Levin, 1985). In this assay, the viral 
glycoprotein expressed on the host cells' plasma membrane is probed by antibody. 
The medium was removed from the microtiter wells and then washed once with a 
solution containing PBS and 0.05 % Tween 20 (PBS-t). This was replaced by 0.2 ml 
of 0.05 % glutaraldehyde (Sigma) in PBS for 15 min at 4 � C . The wells were then 
washed three times with (PBS-t). This was followed by blocking with 0.2ml of 
phosphate-buffered saline (PBS; pH 7.4), containing 1% bovine serum albumin 
(BSA) for 30 min at 37°C. After blocking, washed the wells again for three times 
with PBS-t. The detection antibody, peroxidase-conjugated rabbit anti-HSV-1 
antibody (Zheng et al., 2001) was diluted 1/10000 in 1% BSA in PBS. Each well 
received 0.1 ml of antibody for 1.5 h at 3 7 � C and was then washed three times with 
PBS-t. 0.1 ml of substrate, ortho-phenylenediamine (Sigma) in phosphate-citrate 
buffer (pH 4.8) with 0.005% hydrogen peroxide was added per well. After 30 min 
reaction at 3 7 � C , the plate was briefly agitated, and the OD was read at a wavelength 




Dose-response data were compared using two-way AN OVA with Bonferroni's 
post hoc test. TC50 and TCgo were compared using /-test. One-way ANOVA followed 
by Bonferroni's post hoc test or /-test were used for comparing densitometric data of 
immunoblots. Correlation and linear regression were also used for analysis. 
ANCOVA was used for comparison of slopes of the fitted lines. The purpose of 
ANCOVA is to compare two or more regression lines. Two null hypotheses are tested 
in an ANCOVA. The first is that the slopes of the regression lines are all the same. If 
this hypothesis is not rejected, the second null hypothesis is tested: that the 
Y-intercepts of the regression lines are all the same. It cannot be performed if the 
slopes are significantly different from each other. ;?-value of <0.05 is considered 





Cytotoxicity and anti-herpetic activity of TCS and CHX 
The TC50 (or TCgo), EC50 and Therapeutic index (TI) were calculated and 
summarized in table 3.1. TI is a measure of the specificity of a particular drug. It is 
the ratio of the toxic median dose (TC50) to the effective median dose (EC50). In our 
case, effectiveness refers to the ability of the drug to inhibit HSV replication. A 
higher value of TI means more specific killing, because it implies that the 
concentration requires for inhibiting viral replication (as reflected by the EC50) is far 
lower than that requires to kill the cells (reflected by TC50). 
For 0.01 MOI infection, the calculated TI of TCS is greater than 21.3, which 
coincides with our previous study (Zheng et al., 2001). The TI of CHX is only 1.7, 
reflecting its non-specific antiviral nature. In the case of 0.1 MOI infection, TCS, 
even at concentration higher than 7 )LIM, could not cause 50% (relative to 
mock-infected control) HSV-1 inhibition, suggesting that antiviral activity of TCS 
was overwhelmed due to the presence of large amount of viruses. The TI of CHX in 
the case is 2.7, again accounting for its non-specific antiviral activity. 
The effect of virus dose on cytotoxicity is shown is figure 3.1. Virus 
demonstrates a dose-dependent cytotoxicity on the cells. It is important to note that 
the two virus doses used in this study cause very low cytotoxicity in the cells. 
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Compounds EC50 (nM) TCsoCnM) TCgoCnM) TI 
TCS alone / > 7400 690 ± 94.9 / 
TCS in 0.01 
348 士 70 > 7400 360 ± 120 >21.3 
MOI infection 
TCS in 0.1 
> 7400 > 7400 65 士 16.2 / 
MOI infection 
CHX alone / 845 ± 144 102 士 10 / 
CHX in 0.01 
495 士 56 1186 土 182 402 ± 96 1.7 
MOI infection 
CHX in 0.1 
314±91 > 7100 549 土 141 2.7 
MOI infection 
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Figure 3.1 Cytotoxic effect of HSV-1 infection. HEp-2 cells were infected with 
HSV-1 for 48 h. Viability of the culture, expressed as per cent of mock-infected 
control, was assayed by MTT method. Data are shown as mean 士 SEM (n=3). 
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Selective cytotoxicity of TCS toward HSV-1 infected cells 
As shown in figure 3.2, dose-response curves of TCS on HSV-1 infected and 
mock-infected cells were constructed. One hundred percent cell viability implies no 
cytotoxicity was attributed to TCS. Two virus doses, namely 0.01 and 0.1 MOI, were 
used for infection. In both cases, cytotoxicity of TCS was enhanced in HSV-1 
infected cells across a range of concentration (figure 3.2a and 3.2b). For 0.01 MOI 
infection, selective cytotoxicity ranged from 0.1 to 1.9 )liM, and 0.05 to 1 |iM in the 
case of 0.1 MOI infection. In terms of TCgo, TCS selective cytotoxicity in 
virus-infected cells was statistically significant only in 0.1 MOI infection, suggesting 
that TCS cytotoxic action was a function of virus and also virus dose. Increasing 
virus dose seems to potentiate the cytotoxic action of TCS toward virus-infected cells. 
This sensitization was dose-dependent, which can only be observed in the so-called 
low dosage group (0.05 - 1 |iM), but not in high dosage group (1.85 - 7.4 jiiM). In 
general, this effect diminished gradually with increasing concentration of TCS. 
Western blots were performed to detect the expression level of procaspase-3, the 
ultimate effector caspase in the apoptotic pathway. During apoptosis, procaspase-3 is 
cleaved to form active caspase-3. Therefore, loss of procaspase-3 immunoreactivity 
corresponds to apoptosis induction in our system. As shown in figure 3.3a, more 
apoptosis was observed in cells treated with higher concentration of TCS. 
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Figure 3.2 Dose-response curves for TCS on HSV-1 infected and mock-infected 
HEp-2 cells. HEp-2 cells were infected by HSV-1 for 2 h, followed by 48 h TCS 
treatment. Cell viability was measured by MTT method. 0.01 and 0.1 MOI were used 
for infection and are shown in (a) and (b), respectively. Data are shown as mean ± 
SEM (n=4). *;?<0.05, **/?<0.01, ***；7<0.0001 
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Figure 3.3 Immunoblot for procaspase-3. HEp-2 cells were HSV-infected at 0.1 
MOI or mock-infected, followed by 48 h TCS treatment. In figure (a), densitometric 
data of the immunoblot is shown. Data were normalized and plot in figure (b) and (c). 
Normalization of data is described in the text (p.47). Data from cells treated with low 
concentration of TCS (0.185 iiM) and high (1.85 ^iM) are shown in (b) and (c), 
respectively. Data are shown as mean 士 SEM (n=4). */><0.05. 
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Virus infection alone caused very little apoptosis. Combination of both TCS and 
virus infection induced even more apoptosis when comparing with cells treated by 
either of them. For figure 3.3b and 3.3c, immunoblot data is normalized. A ratio is 
obtained by comparing the protein level in TCS treated-virus-infected cells with 
HSV-1 infected control. In this comparison, the effect of HSV infection on caspase-3 
activation is eliminated. Another ratio is obtained by comparing the protein level in 
TCS-treated cells with mock-infected control. By comparing these two ratios, we can 
contrast caspase-3 activation caused by TCS in HSV-1 infected and uninfected cells. 
These two ratio are presented in figure 3.3b and 3.3c. It is important to note that 
caspase-3 activation was more profound (relative to their respective control) in 
virus-infected cells treated with low concentration of TCS (figure 3.3b). When 
treated with higher concentration of TCS, the extent of caspase-3 activation did not 
differ significantly (figure 3.3c). These data coincide with the dose-response data 
(figure 3.2). 
Anti-apoptotic BCL-2 protein level, as shown in figure 3.4, does not change 
significantly, suggesting that the pro-apoptotic action of TCS, and the antiapoptotic 
action of HSV-1, may not involve the manipulation of the BCL-2 protein level. 
Moreover, the effect of virus dose on BCL-2 level is also not obvious (figure 3.5). 
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Figure 3.4 Immunoblot for BCL-2. HEp-2 cells were HSV infected at 0.1 MOI or 
mock infected, followed by 48 h TCS treatment. In figure (a), densitometric data of 
the immunoblot is shown. Data were normalized and plot in figure (b) and (c). 
Normalization of data is described in the text. Data from cells treated with low 
concentration of TCS (0.185 |liM) and high (1.85 |XM) are shown in (b) and (c), 
respectively. Data are shown as mean 士 SEM (n=4). 
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Figure 3.5 Immunoblot for BCL-2. HEp-2 cells were infected with HSV-1 at 0.01 
and 0.1 MOI for 48 h. Whole cell lysate was prepared and separated by SDS-PAGE. 
Densitometric data are shown as mean 士 SEM (n=4). 
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To consolidate the idea that TCS selectively induces cell death in HSV-1 
infected cells, we perform the same experiment using another cytotoxic agent, 
namely cycloheximide (CHX) to see whether the same phenomenon could be 
observed. Again, dose-response curves were determined (Figure 3.6). In contrast to 
TCS, CHX showed no selective cytotoxicity against HSV-1 infected cells. In fact, 
CHX was less cytotoxic in HSV-1 infected cells than the mock-infected. Again, 
differences in cytotoxicity, in terms of TCgo, were more prominent in 0.1 MOI 
infection (figure 3.6). 
Selective cytotoxicity is implicated in the antiviral activity of TCS 
The anti-HSV activity of TCS was analyzed by ELISA. For 0.01 MOI infection 
(figure 3.7), TCS inhibited HSV-1 replication in an approximately linear fashion. In 
the case of 0.1 MOI infection (figure 3.7), which selective cytotoxicity was observed 
only in the low dosage group but not in high, the pattern of inhibition appeared 
biphasic. Correlation and regression analyses were performed separately on two 
groups. Positive linear correlation between dosage and HSV-1 inhibition was 
observed only in the low dosage group (p<0.0001), but not in the high dosage group. 
The slopes of the fitted lines of the two groups differ significantly (p<0.0001), with 
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Figure 3.6 Dose-response curves for CHX on HSV-1 infected and mock-infected 
HEp-2 cells. HEp-2 cells were infected by HSV-1 for 2 h, followed by 48 h CHX 
treatment. Cell viability was measured by MTT method. 0.01 and 0.1 MOI were used 
for infection and are shown in (a) and (b), respectively. Data are shown as mean 士 
SEM (n=4). */?<0.05, **;?<0.01, ***/?<0.0001. 
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Figure 3.7 Effect of TCS on HSV-1 inhibition in HEp-2 cells. HEp-2 cells were 
infected with HSV-1 at 0.01 MOI (a) and 0.1 MOI (b)，respectively for 2 h. This was 
followed by 48 h TCS treatment. HSV-1 antigen level was quantified by ELISA. Per 
cent reduction in antigen level, relative to HSV-1 infected control, is expressed as 
percent HSV-1 inhibition. Data are shown as mean 士 SEM (n=4). 
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that ofthe low dosage group greater than the high dosage group. This suggests that 
HSV-1 inhibition is more sensitive to the change of TCS concentration in the low 
dosage group than the high dosage group. CHX also demonstrated dose-dependent 
inhibitory effect on HSV-1 replication (Figure 3.8). In contrast to the biphasic pattern 
as observed for TCS, an approximate linear relationship was observed. 
The effect of selective cytotoxicity on TI value 
The two fitted-lines in figure 3.7b were extrapolated to 50 per cent inhibitory 
level. The corresponding TCS concentrations are the EC50. The equations of the 
fitted-lines for low and high dosage group are y = 19.77x + 13.54 and 
y = 0.5973x + 34.01, respectively. By setting y = 50, EC50 can be obtained. E C 5 0 for 
the low and high dosage are 1.84 |iM and 26.77 |iM，respectively. Referring to table 
3.1, TC50 of TCS in uninfected cells is at least 7.4 |xM. Therefore, the TI values for 
the low and high dosage group are at least 4 and 0.28, respectively. The data suggest 
that the dosage group that demonstrates selective cytotoxicity have a higher TI value 
than the one does not. 
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Figure 3.8 Effect of CHX on HSV-1 inhibition in HEp-2 cells. HEp-2 cells were 
infected with HSV-1 at 0.01 MOI (a) and 0.1 MOI (b), respectively for 2 h. This was 
followed by 48 h CHX treatment. HSV-1 antigen level was quantified by ELISA. Per 
cent reduction in antigen level, relative to HSV-1 infected control, is expressed as per 





Any substance that possesses cytotoxicity can inhibit viral replication because 
virus relies obligatorily on host cell machinery for production of viral progeny. 
Reminiscent of the human immune system, cytotoxic 丁 lymphocytes can specifically 
recognize (via antigen presentation by class I major histocompatibility complex 
(MHC) ) and induce apoptosis in virus-infected cells (Gulzar and Copeland, 2004). 
This provides an excellent example which demonstrates selective cytotoxicity can act 
as an antiviral mechanism. 
The current study demonstrates that TCS possesses selective cytotoxicity 
toward virus-infected cells (figure 3.2). This was also confirmed by immunoblot 
analysis of procaspase-3 (figure 3.3). Two virus doses, namely 0.01 and 0.1 MOI, 
were used for infection and the selective cytotoxicity is more obvious in higher MOI 
infection. It appears that virus exerted dose-dependent effect on TCS cytotoxicity, 
supporting the notion that selective cytotoxicity is due to virus infection: when more 
virus was presented, selective cytotoxicity was magnified. Another factor affecting 
selective cytotoxicity is the dosage of TCS. Selective cytotoxicity was observed with 
low dosage of TCS and disappeared at dosage higher than 1.85 |iM (figure 3.2b). At 
the same time, inhibition of HSV-1 replication appeared to parallel the change in 
selective cytotoxicity. Antiviral action of TCS was much more sensitive at low 
dosage when selective cytotoxicity was observed. The antiviral action of TCS is dose 
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dependent and a clear biphasic response is observed (figure 3.7). At low TCS dosage, 
selective cytotoxicity is observed and small change in TCS dosage can produce large 
change in antiviral action. On the other hand, sensitivity decreases at higher dosage 
and the loss of selectivity is presumably due to indiscriminate cell killing. Moreover, 
after data extrapolation, it was found that the TI value for the low dosage group is 
greater than that of the high dosage group. In particular, for high dosage group, the 
estimated TI value is very small (0.28). It reflects the non-specific antiviral nature of 
TCS in this concentration range. This can be accounted by the loss of selective 
cytotoxicity at high TCS concentration (figure 3.2b). On the other hand, for the low 
dosage group, the relatively higher TI value can be attributed to the selective 
cytotoxicity (figure 3.2b). These data demonstrate that the antiviral activity of TCS is 
severely reduced in the absence of selective cytotoxicity. This supports the idea that 
the antiviral activity of TCS is due to selective killing. 
At TCS concentration higher than 1.85 i^ iM, selectivity was not observed but 
survival of cells was still above 50 %. Therefore, TCgo, but not the conventional TC50, 
was employed to demonstrate selective cytotoxicity. One may argue that this 
apparent selectivity is virtually an additive cytotoxic effect of HSV-1 and TCS. This 
possibility is eliminated by the following scheme of comparison: cytotoxicity of TCS 
in virus-infected cells was compared with HSV-1 infected control. The HSV 
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cytotoxic component is therefore eliminated. Cytotoxicity in the virus-infected cell 
cuture is attributed to TCS only. Furthermore, the range of virus dose (MOI 0.01 to 
0.1) used in these experiments did not cause significant change in cell viability 
(figure 3.1). This shows that the viral cytotoxic component in these experiments was 
minimal. Immunoblot study also shows that HSV-1 infection alone did not result in 
significant processing of procaspase-3 (figure 3.3), and the slight decrease in 
immunoreactivity, which may imply increase apoptosis, was also evident in others 
study (Aubert et al., 2007; Galvan et al., 1999). 
As already noted in chapter 2, MOI gives only the average number of virus per 
cell. It implies the heterogenous nature of a given population of virus-infected cells: 
cells were infected with different extent and time. While some groups of infected 
cells were antiapoptotic as expected, others might enter a later stage of infection for 
which viral replication was so rampant and devastating that the cells could no longer 
sustain themselves and apoptosed. The immunoblot data, therefore, only averages the 
expression level in this heterogenous population of cells. 
BCL-2 protein is antiapoptotic in nature and it is logical to hypothesize that its 
expression would be elevated in antiapoptotic-virus-infected cells. Our data, however, 
reveals that its expression level after 48 h HSV-1-infection did not differ from control 
significantly (figure 3.4), and virus dose seems to have no obvious effect on it (figure 
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3.5). This implies that HSV-1 may exert its antiapoptotic effect via mechanisms other 
than elevation of cellular BCL-2 level. These tactics have been discussed in chapter 
1. 
However, it is important to note that in this study, BCL-2 protein level was 
monitored only at the end-point and the temporal change of expression level within 
48 h infection was not followed. Therefore, the possibility of involvement of cellular 
BCL-2 protein as an antiapoptotic mechanism cannot be excluded. 
Selective cytotoxicity is not found in all cytotoxic agents. CHX is used to 
demonstrate that it only possesses cytotoxicity but no selectivity. There is similarity 
between CHX and TCS that they both inhibit protein synthesis. CHX is a 
well-known cytotoxic agent which exerts its effect via translation inhibition in 
eukaryotes resulting in the inhibition of protein synthesis (van Tiel et al., 1985). This 
leads to cell growth arrest and eventually cell death. In addition, CHX has no known 
specific antiviral activity (van Tiel et al., 1985). 
Our data demonstrates that the cytotoxicity of CHX in HSV-1 infected cells 
was in fact attenuated (figure 3.6), suggesting that the infected cells may resistant to 
death. This is not surprising because there are multiple strategies (Cuconati and 
White, 2002; Thomson, 2001; Roulston et al., 1999; Cuff and Ruby, 1996) used by 
viruses to prevent cell death (or promoting cell survival) in order to maximize the 
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production of viral progeny. This is beneficial to the virus and in fact, HSV-1 
infected HEp-2 cells were found to be more resistant to apoptosis induced by CHX 
(Aubert et al., 2007; Aubert et al., 1999). CHX inhibited HSV-1 replication in a 
dose-dependent manner (figure 3.8). This substantiates the notion that killing of cells 
can inhibit viral replication. However, the TI value is only less than two in the case 
of 0.01 MOI infection. It contrasts strongly with that of TCS, which is greater than 
21. This may reflect the role of selective cytotoxicity in the antiviral action of TCS. It 
is important to note that the cytotoxic behavior of TCS resembles CHX when TCS 
concentration is high: they both lack selective cytotoxicity toward HSV-1 infected 
cells. This explains the low TI values in both cases. 
The mechanism for the selectivity is largely unknown. Previous studies 
revealed that the intracellular signal transduction pathway, mitogen-activated protein 
kinases (MAPKs) pathway was implicated in the biological activity of TCS (Huang 
et al., 2006; Ouyang et al., 2006). In light of those studies showing that viruses can 
manipulate the MAPK pathway for their own needs (Hargett et al., 2005; Zachos et 
al., 2001; Zachos et al., 1999; McLean and Bachenheimer, 1999), it was speculated 
that TCS may reverse these signals, thereby inducing premature cell death and 
inhibition of viral replication. For example, temporal activation of p38, a member of 
the MAPK superfamily and induction of BCL-2 in HSV-1 infected Vero cells were 
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found to inhibited by TCS (Huang et al., 2006). However, the real scenario can be 
complicated by the extensive cross-talks between numerous signal transduction 
pathways inside the cells. A resolution of this should rely on proteomic tool which 
reveals, macroscopically and simultaneously, the alternation of various intracellular 
signal transduction processes. 
In this study, although we have shown that TCS induces more cell death in 
HSV-1 infected cells. Apoptosis is a possible mode of cell death as suggested by the 
Western blot data (figure 3.3). Indeed, previous studies have shown that TCS can 
induce apoptosis in vitro (Li et al., 2007; Zhang et al., 2001). There are also 
evidences for viral manipulation of apoptotic pathway (Aubert et al., 2007; Benetti 
and Roizman, 2004; Goodkin et al., 2003; Benetti et al., 2003). Together with the 
MAPK pathway, the interplay between TCS and HSV-1 at these molecular interfaces 
required further investigation. 
As far as we know, there is no known antiviral agent that employs selective 
cytotoxicity as its mechanism of action. The rationale of this mechanism has been 
emphasized in this thesis. Our data support that TCS selectively induces cell death in 
HSV-1 infected cells and this may contributes to its antiviral activity. Similar mode 
of action of TCS had been found in HIV-1 infected cells (Wang et al., 2005). This 
leads to the notion that selective killing of virus-infected may give a generalized 
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account for the antiviral action of TCS. Inquiry on this phenomenon, which is 
grounded on the substantial biological differences between two classes of viruses in 
terms of Baltimore classification, namely, Group I double-stranded DNA virus and 
Group VI single, plus-stranded RNA retrovirus, can be instructive in further 
developing TCS as an antiviral agent. Nevertheless, recent years of findings reveal 
the dark side of TCS: severe side effects including potent immunogenicity, short 
plasma half-life and neurotoxicity were reported (Byers et al., 1994; Byers et al., 
1990). Effort was paid on synthesizing TCS-conjugates, which primarily aim at 
masking the antigenic sites thereby reducing its immunogenicity and increasing its 
molecular size in order to reduce its renal clearance (Wang et al., 2004; He et al., 
1999a; He et al., 1999b; Chan et al., 1999). These approaches, however, can suffer 
from reduced potency of the conjugates (Wang et al., 2004). 
Indeed, the full-length native TCS molecules, being a plant protein, may not be 
suitable to serve as an antiviral drug in the mammalian system due to its potent 
immunogenicity. Nevertheless, it is important to note that central to molecular 
functioning in biological system are non-covalent interactions, which, in biological 
sense, are protein-protein, protein-nucleic acid, protein-lipid interactions. These 
interactions essentially involve only a few critical amino acid residues in the native 
polypeptides. This implies that if we can identify those amino acid residues critical 
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for a particular function which，in this context is the selective cytotoxicity of TCS, 
we can synthesize TCS derivatives with the desirable properties but devoid of side 
effects like immunogenicity. In this regard, TCS is still at the very beginning stage of 
drug development. 
Conclusion 
Our data support that TCS selectively induces cell death in HSV-1 infected 
cells and this may contribute to its antiviral activity. This further supports the 
development of TCS as a potential antiviral therapeutics. 
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